No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis | BMC Research Notes | Full Text

No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis | BMC Research Notes | Full Text



BMC Research Notes

No benefit of longer eradication therapy of Pseudomonas aeruginosa primoinfections in pediatric cystic fibrosis

• F. ClaudeEmail authorView ORCID ID profile,
• I. Rochat and
• G. M. Hafen

BMC Research Notes201912:115

https://doi.org/10.1186/s13104-019-4157-8

©  The Author(s) 2019

• Received: 29 December 2018
• Accepted: 22 February 2019
• Published: 4 March 2019

Abstract

Objective

Patients with cystic fibrosis are more susceptible than members of the general population to lung infections. Infections with Pseudomonas aeruginosa require particular attention, because they may accelerate the deterioration of lung function if not adequately treated. This study assessed the eradication rate of P. aeruginosa primoinfections, with a protocol of inhaled tobramycin and oral ciprofloxacin over a 3 months’ period.

Results

Retrospective single-center study from June 1st, 2007 to December 31st, 2015. Inclusion of 28 pediatric patients (11 females, 17 males), with a total of 49 primoinfections. Overall success rate of 67.3%, which is similar or even inferior to figures published in the literature.

Keywords

• Cystic fibrosis
• Pseudomonas aeruginosa
• Primoinfection
• Eradication protocol